R&D Sponsored 12 Questions with Matthew Goodman LUCENT Biopharma's Medical Director Matthew Goodman, a doctor by training, specialises in late-phase Clinical Development and Medical Affairs.
Digital Sponsored 12 Questions With Navdeep "Navi" Chadha Navdeep "Navi" Chadha is co-founder & CTO of Axtria, a global provider of AI-powered data analytics and cloud software for the life sciences industry.
R&D Sponsored 12 Questions with Faruk Uzman Find out more about Faruk Uzman, VP EMEA at Boston Scientific, in a new 12 Questions With.
R&D Sponsored 12 Questions with Lucy Walker Lucy Walker is the Head of Medical Operations at the growing medical consultancy LUCENT Biopharma. Find out more in a new 12 Questions With.
Sales & Marketing Sponsored 12 Questions with Steve Sanghera Steve Sanghera is the CEO and co-founder of Inventus.
Sales & Marketing Sponsored 12 Questions with Dermot Kenny Dermot Kenny, who leads STEM and Research Partnership at Inizio Advisory, shares his journey from bench scientist to CEO in a new 12 Questions With.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.